OpGen subsidiary Ares Genetics demonstrated feasibility and next generation sequencing based antibiotic susceptibility testing in multi-center study
| | | | |

OpGen subsidiary Ares Genetics demonstrated feasibility and next generation sequencing based antibiotic susceptibility testing in multi-center study

On Apr. 16, 2020, OpGen announced that a study on the feasibility and potential of antibiotic susceptibility testing…

NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence
| | | | | | |

NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence

In 2006, the National Cancer Institute (NCI) launched the TAILORx trial to determine whether gene expression patterns in…